Cytokinetics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) announced that CEO Robert I. Blum will participate in three upcoming investor conferences:

• Jefferies Healthcare Conference on June 9, 2022, at 10:00 AM ET in New York City.
• Goldman Sachs 43rd Annual Healthcare Conference on June 13, 2022, at 2:40 PM PT in Rancho Palos Verdes.
• JMP Securities Life Sciences Conference on June 15, 2022, at 3:00 PM ET in New York City.

Live webcasts will be available on Cytokinetics' website, with replays accessible for 90 days post-event.

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences:

• Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:00 AM ET in a presentation at the Marriott Marquis Hotel in New York City
• Goldman Sachs 43^rd Annual Healthcare Conference on Monday, June 13, 2022 at 2:40 PM PT in a fireside chat at the Terranea Resort in Rancho Palos Verdes
• JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 3:00 PM ET in a fireside chat at the Lotte New York Palace in New York City
  

Interested parties may access the live webcast of these presentations by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(650) 624-3071

FAQ

What events will Cytokinetics CEO Robert I. Blum participate in June 2022?

Robert I. Blum will participate in the Jefferies Healthcare Conference on June 9, the Goldman Sachs 43rd Annual Healthcare Conference on June 13, and the JMP Securities Life Sciences Conference on June 15, 2022.

Where can I watch the Cytokinetics conference presentations?

You can access the live webcasts of Cytokinetics' presentations on their Investors & Media section of the website.

What is the ticker symbol for Cytokinetics?

The ticker symbol for Cytokinetics is CYTK.

How long will the Cytokinetics conference replays be available?

The replays of the Cytokinetics conference webcasts will be available for 90 days following each event.

What is the focus of Cytokinetics as a company?

Cytokinetics focuses on developing muscle activators and inhibitors for diseases involving compromised muscle performance.